10. Since immunotherapy has shown some signs of success, it is reasonable to expect Allison and Honjo will
Answer: A
Allison and Honjo will continue testing immunotherapy as a treatment for cancer.
Given the recent successes of immunotherapy as evidenced by Allison and Honjo's groundbreaking research, it is reasonable to expect that they will continue to explore and refine this treatment approach for cancer.
A) continue testing it as a treatment for cancer.
This option is correct as the extract highlights the significant advancements made in immunotherapy by Allison and Honjo, indicating their ongoing commitment to developing and testing this innovative treatment. Their research has already led to renewed investments in immunotherapy, suggesting that they will persist in this area.
B) focus on other treatments for cancer.
This option is incorrect because the context of the extract emphasizes Allison and Honjo's dedication to immunotherapy rather than shifting focus to other cancer treatments. Their collaborative efforts have specifically targeted T-cell immunotherapy, indicating a sustained focus on this approach.
C) retire soon from the medical community.
This option is incorrect as the extract does not imply any intention for Allison and Honjo to retire. In fact, their continued research efforts and the significant impact of their work suggest that they will remain active in the field.
D) write a book about their Nobel Peace Prize.
This option is also incorrect as there is no indication in the extract that they plan to write a book. The focus is primarily on their research contributions and the implications of their work in cancer treatment, rather than on personal narratives or publications about their award.
Conclusion
The correct answer, A, is supported by the extract's emphasis on the ongoing research and success of immunotherapy spearheaded by Allison and Honjo. Options B, C, and D fail to align with the narrative of their continued commitment to cancer immunotherapy and the significant breakthroughs achieved in this field. This indicates a strong likelihood that they will persist in their efforts to enhance and expand immunotherapy as a viable cancer treatment.